CytoDyn issues letter to shareholders

CytoDyn issued letter to shareholders. “I write today to provide an update on CytoDyn, as we approach the end of our 2024 fiscal year, and to sincerely thank you for your unwavering support. Fiscal year 2024 was a significant year for CytoDyn, and one that I believe will be remembered as the beginning of a turnaround. The Company achieved the lifting of the FDA’s clinical hold in late February 2024 and is now working to return to the clinic. Over the past several months, the Company has made significant internal progress on key initiatives which we believe will lead to marked external developments in the form of the commencement of clinical trials, the rollout of a number of pre-clinical research initiatives, and the continued publication of leronlimab data… Over the next six months, we expect to commence at least one, and potentially two clinical trials. The prospective clinical trials, in order of priority, are: a Phase II study of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer; and a Phase II study exploring leronlimab’s effects on inflammation… Research and development partnership opportunities are important to the Company as we search for cost-effective ways to further build out our product development portfolio. We have identified several such opportunities that we believe are intriguing, and anticipate finalizing agreements with these partners in the very near future… Finally, as promised, CytoDyn has submitted several leronlimab manuscripts for peer review and is in the process of completing final drafts of several others. The clinical endpoint data from the Long COVID trial was recently published in the Journal of Infection. All publications will be available on the Company’s website soon after publication. I believe the Company is building for success and has made significant strides toward initiating a number of key pre-clinical and clinical leronlimab trials.”